The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Blood., Nov;118(19):5250-4 (2011)
TNFÎ± facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
Blood., Dec;118(24):6392-8 (2011)
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.
Blood., Nov;116(22):e111-7 (2010)
Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.
Oncologist., 15(7):744-9 (2010)
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Blood., Oct;116(17):3278-85 (2010)
HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants.
Am. J. Hematol., Nov;84(11):710-4 (2009)
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
Blood., Sep;114(13):2598-605 (2009)
Multi-Site PCR-based CMV viral load assessment-assays demonstrate linearity and precision, but lack numeric standardization: a report of the association for molecular pathology.
J Mol Diagn., Mar;11(2):87-92 (2009)
ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts.
J Mol Diagn., Sep;10(5):475-6; author reply 476 (2008)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.
Blood., Oct;112(8):3330-8 (2008)
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Leukemia., Jun;22(6):1184-90 (2008)
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
J Mol Diagn., Mar;10(2):177-80 (2008)
Biological variability of transferrin saturation and unsaturated iron-binding capacity.
Am. J. Med., Nov;120(11):999.e1-7 (2007)
HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening.
Genet. Test., 11(3):269-75 (2007)
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Clin. Cancer Res., Oct;13(20):6136-43 (2007)
Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screening.
Am. J. Hematol., Feb;83(2):126-32 (2008)
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.
Haematologica., Jul;92(7):970-3 (2007)
Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.
Blood Cells Mol. Dis., 38(3):247-52 (2007 May-Jun)
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Blood., Jun;107(11):4250-6 (2006)
Identification of cytomegalovirus in a liquid-based gynecologic sample using morphology, immunohistochemistry, and DNA real-time PCR detection.
Diagn. Cytopathol., Jun;30(6):411-7 (2004)
Quantitative real-time PCR with automated sample preparation for diagnosis and monitoring of cytomegalovirus infection in bone marrow transplant patients.
Clin. Chem., May;50(5):846-56 (2004)
Clinical news update.
Mol. Diagn., Mar;6(1):69-70 (2001)
Iron beware: a common HFE gene polymorphism may prevent the accurate molecular diagnosis of homozygous hemochromatosis in low-risk, but not high-risk groups.
Hepatology., Feb;31(2):540-2 (2000)
Subspecialty certification examination in molecular genetic pathology.
Mol. Diagn., Sep;4(3):255 (1999)
Hereditary hemochromatosis: impact of molecular and iron-based testing on the diagnosis, treatment, and prevention of a common, chronic disease.
Arch. Pathol. Lab. Med., Nov;123(11):1053-9 (1999)
Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke.
Diagn. Mol. Pathol., Mar;8(1):54-8 (1999)
Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes.
Clin. Chem., Jun;44(6 Pt 1):1356-8 (1998)
Hepatic iron overload: direct HFE (HLA-H) mutation analysis vs quantitative iron assays for the diagnosis of hereditary hemochromatosis.
Am. J. Clin. Pathol., May;109(5):577-84 (1998)
Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C.
Stroke., Jan;27(1):44-8 (1996)
Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C.
Diagn. Mol. Pathol., Sep;4(3):191-7 (1995)
Induction of B cell lymphomas by overexpression of a Myb oncogene truncated at either terminus.
Oncogene., Aug;11(3):525-35 (1995)
Overexpression of C-terminally but not N-terminally truncated Myb induces fibrosarcomas: a novel nonhematopoietic target cell for the myb oncogene.
Mol. Cell. Biol., Apr;14(4):2278-90 (1994)
Effect of glycation of low-density lipoprotein on the immunological determination of apolipoprotein B.
Clin. Chem., Nov;35(11):2219-23 (1989)